Drug Trial Radar · NCT03301168
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Last checked: Nov 19, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 2014
Primary completion
May 11, 2021
Study completion May 2034
Sponsor
- Lead sponsor
- Bellicum PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 26 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).
Conditions
- Acute Lymphoblastic Leukemia
- Leukemia, Acute Myeloid (AML), Child
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Primary Immune Deficiency Disorder
- Osteopetrosis
- Cytopenia
- Hemoglobinopathy in Children
- Anemia, Aplastic
Interventions
BPX-501 T cellsBiological
T cells transduced with CaspaCIDe® safety switch
RimiducidDrug
administered to inactivate BPX-501 cells in the event of GVHD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventTime frame: Month 24
- TRM/NRMTime frame: Day 180, Month 12
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
Stanford University - Division of Pediatric Stem Cell Transplant & Regenerative Medicine
Palo Alto, California
Children's National Medical Center
Washington D.C., District of Columbia
Children's Healthcare of Atlanta
Atlanta, Georgia
Dana-Farber Boston Children's Cancer and Blood Disorders Center
Boston, Massachusetts
Children's Hospital at Montefiore
The Bronx, New York
Oregon Health Sciences University - Doernbecher Children's Hospital
Portland, Oregon
University of Texas Southwestern-Children's Medical Center
Dallas, Texas
Baylor College of Medicine/ Texas Children's Hospital
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.